Builds on existing collaboration with Novartis for pelacarsen, which is currently being evaluated in a Phase 3 cardiovascular outcome study with data expected in 2025 Ionis’ new and advanced technologies will be used to create next generation compound targeting Lp(a) Ionis will receive a $60
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolled Eplontersen is currently under U.S. FDA review for ATTRv-polyneuropathy, with ATTR-CM representing a second, larger potential patient population CARLSBAD, Calif.
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
Companies jointly developing and commercializing eplontersen in the U.S. AstraZeneca adds Latin America as part of its exclusive rights for rest of world CARLSBAD, Calif. , July 28, 2023 /PRNewswire/ — Ionis Pharmaceuticals , Inc. (Nasdaq: IONS) today announced it has expanded its existing
Ionis to hold second quarter 2023 financial results webcast
Webcast scheduled for Wednesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 26, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, August 9 th at 11:30 a.m. Eastern Time to discuss its second quarter 2023
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeks Data further strengthen eplontersen’s differentiated profile, positioning it to be an important potential treatment for patients with ATTRv-PN